These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 15220435)

  • 21. C34, a membrane fusion inhibitor, blocks HIV infection of langerhans cells and viral transmission to T cells.
    Sugaya M; Hartley O; Root MJ; Blauvelt A
    J Invest Dermatol; 2007 Jun; 127(6):1436-43. PubMed ID: 17255952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of an unique CXCR4 epitope whose ligation inhibits infection by both CXCR4 and CCR5 tropic human immunodeficiency type-I viruses.
    Adachi T; Tanaka R; Kodama A; Saito M; Takahashi Y; Ansari AA; Tanaka Y
    Retrovirology; 2011 Oct; 8():84. PubMed ID: 22018245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolated human astrocytes are not susceptible to infection by M- and T-tropic HIV-1 strains despite functional expression of the chemokine receptors CCR5 and CXCR4.
    Boutet A; Salim H; Taoufik Y; Lledo PM; Vincent JD; Delfraissy JF; Tardieu M
    Glia; 2001 May; 34(3):165-77. PubMed ID: 11329179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coreceptor ligand inhibition of fetal brain cell infection by HIV type 1.
    Hibbitts S; Reeves JD; Simmons G; Gray PW; Epstein LG; Schols D; de Clercq E; Wells TN; Proudfoot AE; Clapham PR
    AIDS Res Hum Retroviruses; 1999 Jul; 15(11):989-1000. PubMed ID: 10445811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.
    Hartley O; Gaertner H; Wilken J; Thompson D; Fish R; Ramos A; Pastore C; Dufour B; Cerini F; Melotti A; Heveker N; Picard L; Alizon M; Mosier D; Kent S; Offord R
    Proc Natl Acad Sci U S A; 2004 Nov; 101(47):16460-5. PubMed ID: 15545608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests.
    Miyake H; Iizawa Y; Baba M
    J Clin Microbiol; 2003 Jun; 41(6):2515-21. PubMed ID: 12791875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.
    Jin J; Colin P; Staropoli I; Lima-Fernandes E; Ferret C; Demir A; Rogée S; Hartley O; Randriamampita C; Scott MG; Marullo S; Sauvonnet N; Arenzana-Seisdedos F; Lagane B; Brelot A
    J Biol Chem; 2014 Jul; 289(27):19042-52. PubMed ID: 24855645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
    Blanco J; Barretina J; Clotet B; Esté JA
    J Leukoc Biol; 2004 Oct; 76(4):804-11. PubMed ID: 15258189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.
    Gaertner H; Cerini F; Escola JM; Kuenzi G; Melotti A; Offord R; Rossitto-Borlat I; Nedellec R; Salkowitz J; Gorochov G; Mosier D; Hartley O
    Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17706-11. PubMed ID: 19004761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
    Baba M; Nishimura O; Kanzaki N; Okamoto M; Sawada H; Iizawa Y; Shiraishi M; Aramaki Y; Okonogi K; Ogawa Y; Meguro K; Fujino M
    Proc Natl Acad Sci U S A; 1999 May; 96(10):5698-703. PubMed ID: 10318947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation.
    Polo S; Nardese V; De Santis C; Arcelloni C; Paroni R; Sironi F; Verani A; Rizzi M; Bolognesi M; Lusso P
    Eur J Immunol; 2000 Nov; 30(11):3190-8. PubMed ID: 11093134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines.
    Hartley O; Dorgham K; Perez-Bercoff D; Cerini F; Heimann A; Gaertner H; Offord RE; Pancino G; Debré P; Gorochov G
    J Virol; 2003 Jun; 77(12):6637-44. PubMed ID: 12767983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitivity of primary R5 HTV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors.
    Koning FA; Koevoets C; van der Vorst TJ; Schuitemaker H
    Antivir Ther; 2005; 10(2):231-7. PubMed ID: 15865217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.
    Aquaro S; Menten P; Struyf S; Proost P; Van Damme J; De Clercq E; Schols D
    J Virol; 2001 May; 75(9):4402-6. PubMed ID: 11287590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates.
    Amara A; Vidy A; Boulla G; Mollier K; Garcia-Perez J; Alcamí J; Blanpain C; Parmentier M; Virelizier JL; Charneau P; Arenzana-Seisdedos F
    J Virol; 2003 Feb; 77(4):2550-8. PubMed ID: 12551993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocytosis and recycling of the HIV coreceptor CCR5.
    Signoret N; Pelchen-Matthews A; Mack M; Proudfoot AE; Marsh M
    J Cell Biol; 2000 Dec; 151(6):1281-94. PubMed ID: 11121442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
    Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
    J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.